NCT05818852View on ClinicalTrials.gov

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

June 12, 2023

Study Completion Date

June 28, 2023

Conditions
Pain
Interventions
DRUG

VX-548

Tablets for oral administration.

DRUG

Moxifloxacin

Capsules for oral administration.

DRUG

Moxifloxacin Placebo

Capsules for oral administration.

DRUG

VX-548 Placebo

Tablets for oral administration.

Trial Locations (2)

66219

ICON Lenexa, Lenexa

84124

ICON Salt Lake City, Salt Lake City

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY